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Aims The purpose of this prospective study was to investigate whether internet-based remote moni-
toring offers a safe, practical, and cost-effective alternative to the in-ofﬁce follow-up visits of patients
with an implantable cardioverter deﬁbrillator (ICD).
Methods and results Forty-one patients (62+10 years, range 41–76, 83% male) with previously
implanted ICD were followed for 9 months. One-hundred and nineteen scheduled and 18 unscheduled
data transmissions were performed. There were no device-related adverse events. Over 90% of the
patients found the system easy to use. Physicians reported the system as being ‘very easy’ or ‘easy’
to use and found the data comparable to traditional device interrogation in 99% of the cases. They
were able to address all unscheduled data transmissions remotely. Compared with the in-ofﬁce visits,
remote monitoring required less time from patients (6.9+5.0 vs. 182+148 min, P , 0.001) and
physicians (8.4+4.5 vs. 25.8+17.0 min, P , 0.001) to complete the follow-up. Substitution of two
routine in-ofﬁce visits during the study by remote monitoring reduced the overall cost of routine ICD
follow-up by 524E per patient (41%).









The clinical use of implantable cardioverter deﬁbrillators
(ICDs) has been increasing rapidly since the results of
several randomized trials conﬁrmed the efﬁcacy of ICDs in
the secondary and primary prevention of sudden cardiac
death.
1–3 Patients with ICD require high-quality care and
intense follow-up to ensure safe and effective device per-
formance. According to international guidelines, ICD
patients should be followed at 1- to 4-month intervals,
depending on the device model and the patient’s clinical
status.
2 Given the expanding indications for use and the
complexity of these devices, there is an urgent need to
develop new means of ICD follow-up, so as to optimize
patient safety and the use of healthcare resources. It
has been suggested that an internet-based remote-
monitoring system could provide a practical substitute to
time-consuming and expensive in-ofﬁce visits.
4,5 Although
the initial experience with these systems has been favour-
able,
4,6–8 many practical issues remain. In particular, more
information is required on the usability and safety of
remote monitoring for patient-initiated transmissions and
cost-effectiveness of the system as a substitute for routine
in-ofﬁce visits during long-term follow-up.
In this study, we report the ﬁrst experiences in Europe
with the Medtronic CareLinkTM system. The system consists * Corresponding author. Tel: þ358 8 315 3550; fax: þ358 8 315 2127.
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server, and a password-protected website, where clinicians
can view and analyse patient’s device data (Figure 1). Our
aim was to provide comprehensive data on the safety, clini-
cal practicability, and cost-effectiveness of remote ICD
monitoring in an area characterized by long
travelling distances to the device clinic. The economic
impact of remote ICD monitoring was evaluated by com-
paring the direct and indirect costs of remote follow-up to
those of standard clinical practice.
Methods
Study design and patient population
This prospective, non-randomized single-centre study was con-
ducted between May 2005 and October 2006 in the Oulu University
Hospital, Oulu, Finland. The primary objective of the study was to
evaluate whether an internet-based remote-monitoring service
offers a safe alternative to ofﬁce visits in ICD follow-up. The second-
ary objectives were to assess: (i) the ease of use, satisfaction and
acceptance of data interrogation and transmission by the patients,
(ii) the ease of use and satisfaction of the clinicians with respect
to reviewing device data via the website, and (iii) the travel
burden on the patients and the workload of the clinic in order to cal-
culate the economic impact of remote ICD monitoring.
The study was conducted according to the Declaration of Helsinki
concerning medical research. The protocol was approved by the
Local Medical Ethics Committee. All patients with a previously
implanted ICD that was supported by the Medtronic CareLink
remote-monitoring service were asked to participate in the study.
Only patients with no access to a standard analogue telephone
line or who had a hearing or other physical or mental problem
hindering the use of the system were excluded from the study.
The patients were medically treated at the discretion of the
physician. After giving written informed consent for the study,
each patient was provided with a unique monitor to self-interrogate
the ICD and transmit all data within device memory (e.g. pro-
grammed and measured parameters, diagnostic information includ-
ing all stored intracardiac electrograms and a 10 s real-time sample
of the presenting rhythm) to the central database via a standard
analogue phone line.
Study protocol
According to the study protocol, the ﬁrst remote data transmission
(test) was performed 1–2 weeks after inclusion of the patient into
the study, and a scheduled remote data transmission at 3 and
6 months substituted for the generally recommended in-ofﬁce ICD
follow-up visits. If the subject forgot the data transmission, this
was remedied through a call from a study nurse. A regular follow-up
visit was performed in the hospital at 9 months. The patients were
able to initiate additional remote interrogations due to symptoms
by calling the study nurse or doctor. Likewise, the physicians
were able to increase the frequency of remote interrogations to
monitor elective replacement indicators or if the patient or device
were otherwise considered as requiring more intensive follow-up.
All remote transmissions were evaluated by two experienced
electrophysiologists, who had access to the device information by
logging onto a password-protected and encrypted study-speciﬁc
website. Cross-checking of the data analysis was performed if
either of the electrophysiologists wanted a second opinion. There
was no disagreement between the electrophysiologists in the data
analysis.
Assessment of the system safety and performance
The percentage of successful transmissions that did not require a
troubleshooting phone call was calculated for all data transmissions.
Each of the troubleshooting calls was initially evaluated by the clini-
cal personnel. The complexity of the calls was analysed by whether
the clinical personnel triaged the phone call to a support centre
representative. In addition, detailed information on all technical
problems was collected, and the observations were reviewed by
an independent Adverse Event Advisory Committee (AEAC).
Assessment of the usability of the system
The ease of use, satisfaction with, and acceptance of the remote-
monitoring system were assessed by questionnaires completed by
the patients and hospital staff after each data transmission/evalu-
ation (at test, 3, and 6 months) and in-ofﬁce visit (baseline and
9months). Thepatientswerealsoaskedtorate theiroverallsatisfac-
tion with the remote-monitoring system and whether they preferred
in-ofﬁce visits or remote monitoring. The clinicians’ questionnaire
focused on the usability of the website. In addition, the physicians
were asked to evaluate whether the remote data were comparable
to those obtained during traditional device interrogation.
Assessment of the time burden of the patients
and the device clinic
The effect of remote monitoring on the time burden of the patients
was assessed by comparing the time used for the in-ofﬁce visits
(travel time plus time in the hospital) to the time required to com-
plete the ICD self-interrogation and data transmission. Similarly,
data with regard to time consumption were analysed and compared
for the remote transmissions and in-ofﬁce visits. The time used for
training of the patients by the study nurses was included in the data
analysis.
Assessment of the economic impact of remote
implantable cardioverter deﬁbrillator monitoring
Both the direct and indirect expenditures of ICD follow-up were
analysed. The municipalities were responsible for the direct cost
of regular ICD follow-up of their residents except for a 22E fee
per visit paid by the patient. The indirect cost reimbursed by the
Social Insurance Institution of Finland (KELA) consisted of travel
and accommodation costs and sickness allowance for the patients
and accompanying persons. All travel costs of the patients and
necessary escorts in excess of a ﬁxed co-payment (9.25E per
one-way trip) were refunded by the KELA. If the patients or the
accompanied persons had to make an overnight stop due to
reasons associated with the disease, they were also entitled to an
accommodation allowance. Sickness allowance represents a com-
pensation for income lost due to temporary incapacity for work.
In this study, the average reimbursement paid by the KELA
(44.00E/day) was used in the calculations, although the actual
cost for the employers may have been greater.
Figure 1 Medtronic CareLink remote-monitoring system. Adapted
from Schoenfeld et al.
6 The system consists of a portable patient
monitor, central database in secure server, and a password-
protected website, where clinician can view and analyse patient
device data.
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consisted of the payments to the hospital. During the course of
the study, the use of the CareLink network and data evaluation by
the physicians was free of charge. Therefore, currently effective
prices of these services were used in the economic calculations.
At Oulu University Hospital, the fee for the remote follow-up
service is covered by the remote transmission evaluation fee,
which is paid completely by the municipalities.
Statistical analysis
Descriptive statistics were used to summarize a patient’s satisfac-
tion with the monitor. Missing answers were reported in the
tables/ﬁgures as ‘missing’. All data are shown as mean+SD or
frequencies (with percentages). To assess subject safety with
respect to the use of the CareLink network, the primary endpoint
of the study was to calculate the upper one-sided 90% exact conﬁ-
dence interval (CI) for the rate of unanticipated serious adverse
device effects (USADEs). USADEs were identiﬁed from the adverse
event information. It was calculated that if no subject out of 30
patients experienced any adverse events the USADE rate with 90%
CI would be , 7.5%. It was conservatively estimated that 25% of
the subjects would not complete the protocol. Therefore, a
minimum of 40 subjects were to be enrolled into the study.
Results
Subject demographics
Forty-one patients (34 males and 7 females) with a pre-
viously implanted ICD supported by the Medtronic CareLink
remote-monitoring service were included in the study. The
mean age of the patients was 62+10 years (range 41–76
years). The indication for the ICD implantation was second-
ary prevention of sudden cardiac death in 37 (90%) patients
and primary prevention in 4 (10%) patients. Thirty patients
(73%) had prior myocardial infarction and 5 (12%) had
dilated cardiomyopathy. Most of the patients were in
stable clinical condition as only one patient (2%) had
New York Heart Association III symptoms and no patients
were in class IV (Table 1). The most common symptoms
at study inclusion included occasional dyspnoea (32%) and
palpitations (34%). The implanted devices consisted of
Medtronic GEM family VR (n ¼ 21) and DR (n ¼ 3), Marquis
VR (n ¼ 6), Maximo DR (n ¼ 3) and VR (n ¼ 6), and biventri-
cular InSync ICD (n ¼ 2).
System safety and performance
No device-related adverse events and four technical obser-
vations were reported during the study. All independent
AEAC members agreed that these observations were not
adverse events. Hence, the rate of USADEs was ,7.5%,
and the safety objective was met.
Over 90% (95% CI: 85–95) of the data transmissions were
performed without troubleshooting phone call. All trouble-
shooting calls occurred during the test transmissions. Ten
of 12 troubleshooting calls were easily resolved by the
patient, the hospital, or the telephone operator. In two
cases, the patient monitor was replaced because of pro-
blems in connecting the monitor to the phone line. None
of the problems remained unresolved after contact with
the system helpline representative, and the data were
always correctly displayed on the website.
Ease of use and satisfaction
Patients’ ease of use and satisfaction are depicted in
Figure 2. There were no statistically signiﬁcant differences
in the distribution of the patients’ replies at test, 3,
6 months, and unscheduled visits. Therefore, the values in
Figure 2 represent the data for all remote transmissions.
The majority of the patients found the clarity of the
written instructions ‘very clear’ or ‘clear’. Likewise, posi-
tioning of the antenna and setting up the monitor were
‘very easy’ or ‘easy’ for most patients, and 80% of the
remote-monitoring sessions were performed by the patients
without any assistance. The overall judgement was that the
use of the patient monitor was better than expected in 40%
of the cases and as expected in 54%.
Clinicians’ ease of use and satisfaction are depicted in
Figure 3. As there were no statistically signiﬁcant differences
in the distribution of the clinicians replies at the various
transmission times, the values in Figure 3 represent the
data for all remote transmissions. Almost all transmissions
(97%) were reported by the physicians as being ‘very easy’
or ‘easy’ to access on the website, while website navigation
Figure 2 Patient’s satisfaction with the use of the system. Answers
are represented at a scale from zero to four. Clarity of written
instructions: 4 ¼ very clear, 3 ¼ clear, 2 ¼ unclear, 1 ¼ very
unclear; setup of CareLink monitor/positioning of the antenna/
overall judgement of monitor: 4 ¼ very easy, 3 ¼ easy, 2 ¼ difﬁcult,
1 ¼ very difﬁcult; time needed for transmission: 4 ¼ very short,
3 ¼ short, 2 ¼ long, 1 ¼ very long.
Table 1 Clinical characteristics of the patients
Age (years) 62+19 (range 41–76)
Sex (male/female) 34 (83%)/7 (17%)
ICD indication
Primary prevention 4 (10%)
Secondary prevention 37 (90%)
LVEF (%) 43+15
NYHA class (I/II/III/IV) 15/25/1/0
Prior MI 30 (73%)
Prior CABG 19 (46%)
Non-ischaemic cardiomyopathy 5 (12%)
LQTS 2 (5%)
The numbers are mean+SD. ICD, implantable cardioverter deﬁbrilla-
tor; NYHA, New York Heart Association; LVEF, left ventricular ejection
fraction; MI, myocardial infarction; CABG, coronary artery bypass graft-
ing; LQTS, long QT syndrome.
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with the performance of the system and found the data com-
parable to traditional device interrogation in the majority
of the cases. In 2 of 137 cases, the physicians felt that an
in-ofﬁce visit would have provided more detailed information
of the device function, because it was not possible to
measure the pacing threshold remotely.
Effect of remote monitoring on the time burden
of the patients and the device clinic
The time needed by the patients for remote data trans-
mission (6.9+3.7 min, range 2.3–17.5 min) was signiﬁ-
cantly shorter than the duration (travel time þ time in the
hospital) of an in-ofﬁce visit 391+282 min (range 41–
1346 min), P , 0.001. The average one-way distance and
travel time to the hospital were 130+95 km (range 3–
350) and 182+148 min (range 10–670 min), respectively.
Most patients (90%) classiﬁed the time needed for the
remote data transmission for all follow-ups as very short
(21%) or short (69%).
The impact of remote monitoring on the time burden of
the physicians and additional hospital staff is presented in
Figure 4. The time needed by the physician for reviewing
device data on the secured website (8.4+4.5 min, range
2–30 min) was signiﬁcantly shorter than the time needed
for completing an in-ofﬁce follow-up (25.8+17.0 min,
range 5–90 min), P , 0.001. In keeping with this, it was
more time-consuming also for the additional hospital staff
to complete an in-clinic visit than remote monitoring
(45.3+30.6 min vs.9.3+15.9 min, P , 0.001).
Economic impact of remote monitoring
During the study, two generally recommended in-ofﬁce visits
were substituted by remote data transmission. A routine ICD
follow-up, including clinical and device evaluation by a cardi-
ologist, at Oulu University Hospital costs 210E.T h eu s eo ft h e
monitor was free of charge to the patients and they called a
toll-free number. The fee to the municipality was 55E per
transmission evaluation (i.e. the same as for a paper consul-
tation). Thus, replacement of an in-ofﬁce visit by a remote
data transmission reduced the direct costs of ICD follow-up
to the healthcare providers by 155E. In addition, the patients
saved 22E because they did not have to pay the fee for an
outpatient visit. Accordingly, compared with the generally
recommended ICD follow-up scheme, remote monitoring
reduced the direct cost ICD follow-up among the study popu-
lation from 38 048E to 23 534E (38%) (Table 2).
The average distance to the device clinic was 130+95 km
(range 3–350). The majority of the patients used their own
car to travel to the device clinic (66 visits). Other transpor-
tation modes included taxi (seven visits) and public trans-
portation (six visits).The KELA reimbursed patients for
travelling by public transportation or for using their own
car at 0.20E/km, by a taxi at 1.16E/km, plus a starting
fee of 4.50E. The average travelling cost of the patients
and the accompanying persons was 74.36+103.88E
(range 1.20–797.80E) per outpatient visit. In contrast, no
travelling expenses were caused by remote data trans-
missions. One patient had to make an overnight stop when
visiting the device clinic. The accommodation allowance
paid by the KELA was 20.18E per night, and the total cost
of accommodation among the study population was 20.18E.
In nine instances the patient (11%) and in 10 instances an
accompanying person (12.5%) had to be on sick-leave because
of the routine in-ofﬁce visits. By using the average value of
daily sickness allowance (44.00E/day), it was calculated that
the cost for the sickness allowance during the study period
was836E. Nosubjectswere onsickleavedue toremote moni-
toring. Eliminating the need for travelling and sickness allow-
ance during remote monitoring reduced the indirect cost of
ICD follow-up by 6954E. In summary, among the study popu-
lation, substitution of two in-ofﬁce visits during the 9-month
follow-up period by remote monitoring accounted for a
savings of 21 468E (41%) in the total cost (Table 2).
There were 18 unscheduled patient- or physician-initiated
data transmissions during the study period. In all of these
cases, the physicians were able to address the problems
remotely and there was no need for additional travelling
and daily sickness allowance. An example of a symptom-
initiated data transmission is shown in Figure 5. If the
patients had had to visit the hospital for reassurance, the
additional cost to the city would have been 2790E
(18   155E), 1060.10E to the KELA, and a total of 990.60E
tothepatients.Thecostforpatientsconsistsoffeefortravel-
ling and in-ofﬁce visits. The cost for the KELA consists of the
remainderofthetravelcost(averagetraveldistance187.5+
111.6 km) and sickness allowance of 2 days (one for the
patient and one for the accompanying person).
Discussion
Our data indicate that remote ICD monitoring with the
Medtronic CareLink system provides a safe, practical, and
Figure 3 Physician satisfaction with the use of the system.
Answers are represented at a scale from zero to four. Access to
web data/Navigation CareLink website: 4 ¼ very easy, 3 ¼ easy,
2 ¼ difﬁcult, 1 ¼ very difﬁcult; overall satisfaction about CareLink
monitor: 4 ¼ very satisﬁed, 3 ¼ satisﬁed, 2 ¼ unsatisﬁed, 1 ¼ very
unsatisﬁed.
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The system was easy to use and both the patients and hospital
staff were satisﬁed with it. In addition, compared with
the generally recommended routine ICD follow-up scheme,
remote monitoring diminishes the annual cost of ICD
follow-up by 524E (41%) per patient in an area characterized
by long travelling distances to the device clinic.
Safety and practicability of remote implantable
cardioverter deﬁbrillator monitoring
According to international guidelines, patients with ICDs
should be followed at 3-month intervals, depending on
the device model and the patient’s clinical status.
2 As no
adverse events were reported during the 9-month study
period, remote monitoring with the Medtronic CareLink
service was proven safe. This indicates that at least two of
four routine in-ofﬁce ICD follow-up visits can be replaced
by remote monitoring without compromising patient safety.
In line with the results of previous studies, both the physi-
cians and patients were satisﬁed with the performance of
the remote-monitoring system in routine ICD follow-up.
5,6
Since all unscheduled data transmissions were resolved
using the remote-monitoring system, our data suggest that
remote monitoring can be safely used to evaluate symptoms
of the patients and to detect potential problems with the
device (e.g. depletion of the battery). This eliminates the
need for unwarranted trips to the emergency room and
device clinic, which is like to alleviate the anxiety of the
patients as remote monitoring provides a prompt response
to their concerns. Recently, remote monitoring with auto-
matic data transmission has also been shown to improve
Figure 4 Time burden for the hospital staff. The graph represents the mean time in minutes+SD that is needed for the clinician and nurse
to do the follow-up of a patient in the ofﬁce vs. the time needed to evaluate a transmission.
Table 2 Comparison between the cost of ICD follow-up according to the generally applied follow-up scheme and the study protocol
among our population (n ¼ 41)
Generally applied follow-up scheme Study protocol Savings
Number of scheduled visits
In-ofﬁce visits* 164 82
Remote data transmission** 0 82
Direct cost
In-ofﬁce visit (210E per visit) 34 440.00E 17 220.00E 17 220.00E
Remote monitoring (55E per visit) 0.00E 4510.00E 24510.00E
Patient fee (22E per in-ofﬁce visit) 3608.00E 1804.00E 1804.00E
Indirect cost
Traveling (77.68E per in-ofﬁce visit) 12 195.04E 6097.52E 6097.52E
Accommodation (20.18E/night) 40.36E 20.18E 20.18E
Sickness allowance (44E/day) 1672.00E 836.00E 880.00E
Total costs 51 955.40E 30 487.70E 21 467.70E
Total costs per patient 1267.20E 743.60E 523.60E
*According to the generally applied follow-up scheme and the study protocol, every patient (n ¼ 41) would have had four and two in-ofﬁce visits during
the 9 months follow-up period, respectively.
**According to the study protocol, every patient conducted two remote transmissions during the study period, whereas no remote transmissions would
have been conducted according to the generally applied follow-up scheme.
Remote ICD follow-up 1149the early detection of device malfunction and asymptomatic
arrhythmias such as atrial ﬁbrillation.
6,9,10 This enables
proactive device- and medical therapy and allows better
monitoring of the efﬁcacy of therapeutic interventions
among high-risk patients. In our study, antiarrhythmic medi-
cation was optimized in six cases under remote surveillance.
Time burden of the patients and device clinics
As all data gathered during a normal in-ofﬁce device
interrogation can be sent remotely to the device clinic for
evaluation, the patients and accompanying persons save
time by using the CareLink network. The average timesaving
was 3 h per patient per visit and it was directly related to
the travelling distance to the device clinic.
In our study, two of four in-ofﬁce visits were substituted
by remote monitoring. This means that during the study
period, the physicians would have had 45 min and the
other hospital staff 90 min more time for other activities
per patient, respectively. Although it is obvious that the
time saved will release resources for other activities, the
economic value of this remains to be established.
Clinical usability of the CareLink network and
comparison with other remote implantable
cardioverter deﬁbrillator monitoring systems
Our analysis reveals that remote monitoring can reduce the
number of routine follow-up visits by at least half without
compromising patient safety. Like other investigators,
5,6,11
we demonstrated that remote transmission of ICD data is
not only safe but also extremely convenient for patients
and clinicians. One of the major beneﬁts of the CareLink
network is that practically all Medtronic ICDs that can be
interrogated with the programmer can also transmit data
through the network, whereas some of the other available
systems operate only with the latest ICD models with a
speciﬁc transmitter inside the device.
4,12
However, we also identiﬁed limitations for the clinical
usability of the system. The main problem of the present Car-
eLink network is that device data must be transmitted via a
standard analogue phone line. In Finland, there are currently
5.7 million cellular phones (108 per 100 inhabitants) and
only 1.9 million analogue phone lines (http://www.stat.ﬁ/
til/tvie/tau_en.html). Thus, it is not surprising that presently
50% of the patients in our hospital district cannot use the
system. Therefore, a system that can send data automatically
via a mobile phone network
4,12 would be a more attractive
alternative in our area, especially if it can also support
older devices. During this study, patient co-operation was
essential for data transmission. In contrast, the latest
version of the CareLink network supports automatic wireless
data transmission from the device to the patient monitor,
making the system even more user-friendly for patients
implanted with an ICD supporting automatic wireless trans-
mission and alerts. Finally, it should be emphasized that
remote programming of the device is not possible in any of
the commercially available remote follow-up systems. In
the current study, we found problems in two patients in
that it was not possible to measure the pacing threshold
remotely. In the latest ICD model, the threshold measure-
ment and adjustment are done automatically, which, in con-
junction with automatic data transmission, is likely to
improve the safety of pacemaker-dependent patients.
Cost-effectiveness of remote implantable
cardioverter deﬁbrillator monitoring
As a result of expanding indication for use and complexity of
the devices, the costs associated with ICD follow-up have
risen sharply over the past several years. We calculated
that the substitution of two scheduled routine in-ofﬁce
visits by remote monitoring reduced the total expenditure
of ICD follow-up by 524E per patient during the 9-month
study period. In addition, an average of 100E per patient
was saved, because all unscheduled data transmissions
(n ¼ 18) during the study period were solved remotely and
Figure 5 Interval (V–V) plot (A) and intracardiac ECG (B) obtained during an unscheduled data transmission. The patient had occasional
palpitation about once a month. The remote data transmission revealed a fast VT episode that was appropriately treated by the device
with single burst pace therapy and there were no need for an in-ofﬁce visit.
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ance. Thus, depending on the number of unscheduled visits,
it can be calculated that the annual saving of remote moni-
toring in our hospital district is 524–749E per patient. This
suggests that even in centres with shorter distances to the
device clinic and longer than generally recommended
follow-up intervals, the cost of the ICD follow-up would be
reduced if every other routine in-ofﬁce visit is substituted
by remote monitoring, and the majority of the symptom-
related episodes were solved remotely.
The major indirect cost driver in the ICD follow-up is tra-
velling to the hospital. Therefore, the greatest cost beneﬁt
is expected among patients who live far away from the
device clinic and are still actively working (not retired).
Fauchier et al.
13 calculated recently that remote monitoring
reduced the overall cost of ICD follow-up when the distance
between home and the device clinic was .100 km. The
saving is obvious also among patients with primary preven-
tion indication for ICD implantation.
14 In Western Europe,
160 ICDs per million inhabitants are implanted annually.
On the basis of our results, it can be calculated that if
remote monitoring were to be applied to all the patients
with new ICDs, the annual saving for the healthcare
system would be 16–23 million euros. In addition, remote
monitoring gives physicians extra time to counsel patients
with critical conditions, ensuring medical efﬁciency, and
better overall patient management, which is expected to
reduce the cost of the treatment even further.
Limitations
Deﬁning medical costs is a complicated process, because
medical prices are typically based upon a patient’s needs
and/or the relationship with a particular insurance ﬁrm or
healthcare provider. Therefore, our results cannot be
directly extrapolated to other countries and healthcare
systems. Nevertheless, it is likely that remote monitoring
would save a substantial amount of time and money, regard-
less of the economic system. As the primary aim of this study
was to evaluate the safety and feasibility of remote ICD
monitoring, further prospective randomized studies are
needed to identify patients who would beneﬁt most from
proactive device follow-up and improved monitoring of the
efﬁcacy of therapeutic interventions.
Conclusions
The launch of remote monitoring is an important milestone
in the management of ICD patients. It provides a tremendous
convenience for patients and clinicians and reduces the cost
of follow-up. Although the technology is not intended to
replace direct patient contacts completely, it can indeed
release resources for other activities and help to maintain
proactive patient care.
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